| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From INSERM Unité 360 (Drs. Brandel, Delasnerie-Lauprêtre, and Alpérovitch), Hôpital de la Salpêtrière; the Service de Biochimie et Biologie Moléculaire (Dr. Laplanche), Hôpital Lariboisière; and the Laboratoire de Neuropathologie Raymond Escourolle et Coordinateur du Réseau Français de Neuropathologie (Dr. Hauw), Hôpital de la Salpêtrière, Paris, France.
Address correspondence and reprint requests to Dr. J.P. Brandel, INSERM Unité 360, Hôpital de la Salpêtrière, 75651 Paris cedex 13, France; e-mail: brandel{at}chups.jussieu.fr
OBJECTIVE: To assess the effect of usage of three different versions of Creutzfeldt-Jakob disease (CJD) diagnostic criteria on estimates of CJD incidence.
METHODS: A total of 428 patients referred for suspected sporadic CJD between 1991 and 1997 were classified according to different criteria to be compared after analysis of medical records. Specificity, sensitivity, and positive and negative predictive values were calculated for each set of criteria in the subgroup of patients with a postmortem examination. Positive and negative predictive values of the clinical diagnosis were applied to cases without postmortem examination. Subsequently, the true number of cases of CJD among the referred cases was estimated.
RESULTS: By comparison with the French and European study criteria, the Masters’ criteria showed higher sensitivity but lower specificity and positive predictive value. Comparison with an estimate of the true total number of CJD cases showed that Masters’ criteria overestimated the incidence by 7%, whereas the French and the European study criteria led to an underestimate of 12%. Detection of the 14-3-3 protein in CSF, considered as an additional diagnostic criterion for clinically probable CJD, resulted in a slight increase in the estimated incidence when the French or European study criteria were applied.
CONCLUSIONS: Different diagnostic criteria could lead to an under- or overestimation of the true incidence of CJD. Therefore, comparisons of CJD incidence in different countries should rely on diagnostic classifications using identical criteria. Taking into account 14-3-3 protein detection as a criterion for probable CJD will result in a small increase in the estimated CJD incidence.
Key words: Creutzfeldt-Jakob disease—Clinical criteria.
This article has been cited by other articles:
|
|
 |
|
  U. Heinemann, A. Krasnianski, B. Meissner, D. Varges, K. Kallenberg, W. J. Schulz-Schaeffer, B. J. Steinhoff, E. M. Grasbon-Frodl, H. A. Kretzschmar, and I. Zerr Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance Brain, May 1, 2007; 130(5): 1350 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sanchez-Juan, A. Green, A. Ladogana, N. Cuadrado-Corrales, R. Saanchez-Valle, E. Mitrovaa, K. Stoeck, T. Sklaviadis, J. Kulczycki, K. Hess, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology, August 22, 2006; 67(4): 637 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Nozaki, T. Hamaguchi, M. Noguchi-Shinohara, K. Ono, H. Shirasaki, K. Komai, T. Kitamoto, and M. Yamada The MM2-cortical form of sporadic Creutzfeldt-Jakob disease presenting with visual disturbance Neurology, August 8, 2006; 67(3): 531 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Horvath, A. Coeytaux, P. Jallon, T. Landis, P. Temperli, and P. R. Burkhard Carbamazepine encephalopathy masquerading as Creutzfeldt-Jakob disease Neurology, August 23, 2005; 65(4): 650 - 651. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Glatzel, K. Stoeck, H. Seeger, T. Luhrs, and A. Aguzzi Human Prion Diseases: Molecular and Clinical Aspects Arch Neurol, April 1, 2005; 62(4): 545 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Haik, J. P. Brandel, D. Salomon, V. Sazdovitch, N. Delasnerie-Laupretre, J. L. Laplanche, B. A. Faucheux, C. Soubrie, E. Boher, C. Belorgey, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects Neurology, December 28, 2004; 63(12): 2413 - 2415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Huang, S. K. Marie, J. A. Livramento, R. Chammas, and R. Nitrini 14-3-3 protein in the CSF of patients with rapidly progressive dementia Neurology, August 12, 2003; 61(3): 354 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. d'Aignaux, S. N Cousens, N. Delasnerie-Laupretre, J.-P. Brandel, D. Salomon, J.-L. Laplanche, J.-J. Hauw, and A. Alperovitch Analysis of the geographical distribution of sporadic Creutzfeldt-Jakob disease in France between 1992 and 1998 Int. J. Epidemiol., April 1, 2002; 31(2): 490 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. G. Esteban, B. Atares, J. J. Zarranz, F. Velasco, and I. Lambarri Dementia, Amyotrophy, and Periodic Complexes on the Electroencephalogram: A Diagnostic Challenge Arch Neurol, October 1, 2001; 58(10): 1669 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J E Green, E J Thompson, G E Stewart, M Zeidler, J M McKenzie, M-A MacLeod, J W Ironside, R G Will, and R S G Knight Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease J. Neurol. Neurosurg. Psychiatry, June 1, 2001; 70(6): 744 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Lanska, I. Zerr, and S. Poser Diagnosis of Creutzfeldt-Jakob disease: Effect of clinical criteria on incidence estimates Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease Neurology, May 22, 2001; 56(10): 1422 - 1423. [Full Text] [PDF]
|
|
|
|
|
|
S. Haik, J. P. Brandel, V. Sazdovitch, N. Delasnerie-Laupretre, K. Peoc'h, J.-L. Laplanche, N. Privat, C. Duyckaerts, J. L. Kemeny, N. Kopp, et al. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease Neurology, November 14, 2000; 55(9): 1401 - 1404. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
